StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Biologics & Drug Substance Complex Menges, Slovenia by Year

Biologics & Drug Substance Complex Menges, Slovenia (m²)

Novartis Biologics & Drug Substance Complex Menges, Slovenia: 166,591 in FY2025, unchanged from a year earlier.

Latest, FY2025
166,591
Period ended Dec 31, 2025
Change on a year earlier
0.0%
166,591 in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below

Where the FY2025 figure comes from

“|| Menges, Slovenia | 166 591 | Production of small molecules and large molecules drug substances and drug intermediates; Research and development for Biologics”

Source: Novartis Form 20-F (0001114448-26-000004) ↗

Reported in Form 20-F Item 4.D.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBiologics & Drug Substance Complex Menges, Slovenia (m²)Year on yearSource
FY2025Dec 31, 2025166,5910.0%Novartis Form 20-F (0001114448-26-000004) ↗
FY2024Dec 31, 2024166,591+24.5%Novartis Form 20-F (0001370368-25-000004) ↗
FY2023Dec 31, 2023133,763–Novartis Form 20-F (0001370368-24-000004) ↗

Cite this data

StockData. (2026). Novartis Biologics & Drug Substance Complex Menges, Slovenia, annual FY2023–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/fac-menges-m2

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.